Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis

Objective of the Paper: To demonstrate a case of successful use of tocilizumab in a child with systemic juvenile idiopathic arthritis (JIA). Key Points. A clinical variant of JIA is systemic arthritis (systemic JIA). Currently, management of systemic JIA includes tocilizumab, a recombinant humanised anti–interleukin-6 receptor monoclonal antibody. The article describes a case of successful use of tocilizumab in a child with systemic JIA after inefficient therapy with glucocorticosteroids and methotrexate. Conclusion. Systemic JIA is the severest clinical JIA variant. Tocilizumab allows achieving the quiescent disease stage where the standard therapy with glucocorticosteroids and methotrexate is ineffective. Keywords: system arthritis, juvenile idiopathic arthritis, tocilizumab, children.

[1]  E. Alexeeva,et al.  AB0930 EFFICACY OF TOCILIZUMAB IN TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME , 2019, Abstracts Accepted for Publication.

[2]  K. Minden,et al.  Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis , 2019, The Journal of Rheumatology.

[3]  K. Amano,et al.  Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis , 2018, Modern rheumatology.

[4]  K. Minden,et al.  Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry , 2017, Arthritis Research & Therapy.

[5]  H. Brunner,et al.  Tocilizumab for treating juvenile idiopathic arthritis , 2016, Expert opinion on biological therapy.

[6]  A. V. Vitebskaya,et al.  Dynamics of growth of children with systemic form of juvenile idiopathic arthritis during therapy with tocilizumab and other biological agents , 2016 .

[7]  T. Bzarova,et al.  Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case , 2016 .

[8]  Н. В. Любимова,et al.  Влияет ли инфицированность и активация инфекций на эффективность лечения увеита генно-инженерными биологическими препаратами? , 2015 .

[9]  Т. В. Шилова,et al.  Особенности иммуногенетического профиля русской популяции детей Челябинской области, страдающих ювенильным идиопатическим артритом , 2006 .